The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

HIV prevention messages selected using machine learning from existing social media content were found to be appealing to gay and bisexual men and public health departments in the United States, ...

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week found that so far relatively few people with HIV are taking ...

Two new long-acting antiretroviral drugs, VH-184 and VH-499, have demonstrated similar potency to the best available antiretrovirals currently in use in phase 2a proof-of-concept trials, according to ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

A symposium at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month included presentations advocating changes in practice on what might be called opposite ends of ...

Des antirétroviraux à prise hebdomadaire à l'horizon Image carballo/Shutterstock.com Deux antirétroviraux susceptibles d'être pris par voie orale une fois par semaine ont été dévoilés lors du 31ème ...

The DoxyPEP trial enrolled more than 500 gay and bisexual men and transgender women in San Francisco and Seattle who were either living with HIV or taking PrEP. In 2022, Professor Annie Luetkemeyer of ...

A positive diagnosis continues to be a source of isolation and stigma for people living with HIV, especially among trans people, younger people and women. Findings from the UK’s largest survey of ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...